Inogen's Stock Collapses After Earnings Call Addressing Short-Seller Concerns
Executive Summary
Inogen acknowledged data from its previous research firm were inaccurate on its latest investor call. A short seller recently called out Inogen for what it claimed was an overstatement of its market potential and economic projections, and has asked the company to clarify its estimates.
You may also be interested in...
Muddy Waters Short-Sells Inogen, Citing Inflated Market Projections
The short seller that took on St. Jude Medical two years ago on cardiac-device cybersecurity now is targeting Inogen, maker of portable oxygen concentrators. Muddy Waters says the research firm that projected Inogen’s market penetration is way off and the company’s leadership is far too optimistic.
Massive Family Dollar Rat Infestation Leads To Multi-State Recall
The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.
Digital Health Roundup: Exec Chats With Illumina, Bloom, AngelMed; M&A, Funding; FDA Down-Classifies Apps
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights IBM Watson Health’s divestiture and other financing news, Exec Chats with Illumina, AngelMed and Bloom, Philips’ new hand-held ultrasound device and autonomous robotic surgery, as well as the latest FDA news on digital health.